Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Butters, 2010 Miles, 2002, Combination versus sequential single-agent therapy in metastatic breast cancer, Oncologist, 7, 13, 10.1634/theoncologist.2002-0013 Toogood, 2005, Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6, J Med Chem, 48, 2388, 10.1021/jm049354h Finn, 2016, Palbociclib and letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303 Brady, 1997, Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument, J Clin Oncol, 15, 974, 10.1200/JCO.1997.15.3.974 EuroQoL, 1990, EuroQol—a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 Zhou, 2009, Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment, Breast Cancer Res Treat, 117, 577, 10.1007/s10549-009-0310-8 Eton, 2004, A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale, J Clin Epidemiol, 57, 898, 10.1016/j.jclinepi.2004.01.012 Fitzmaurice, 2011 Brucker, 2005, General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G), Eval Health Prof, 28, 192, 10.1177/0163278705275341 Harbeck, 2016, Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 27, 1047, 10.1093/annonc/mdw139 Campone, 2013, Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy, Curr Med Res Opin, 29, 1463, 10.1185/03007995.2013.836078